Indivior outlines 30% adjusted EBITDA growth target for 2026 with new $400M share repurchase program
Source: SeekingAlpha
2026-02-26 18:29:03 ET
More on Indivior
- Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Indivior
- Historical earnings data for Indivior
- Financial information for Indivior
Read the full article on Seeking Alpha
For further details see:
Indivior outlines 30% adjusted EBITDA growth target for 2026 with new $400M share repurchase program
Indivior PLC
NASDAQ: INDV
INDV Trading
1.08% G/L:
$32.22 Last:
862,090 Volume:
$32.12 Open:
INDV Latest News
INDV Stock Data
$4,174,798,177
123,522,122
1.6%
31
N/A
Pharmaceuticals
Healthcare
GB
North Chesterfield
